To support the primary role of SLC26A3 in the pathogenesis, SLC26A3 polymorphisms and downregulation have been linked to intestinal inflammation in non-CLD subjects [6,7] and no changes in fecal microbiota characterize CLD-associated IBD [8]. Here, SLC26A3 is linked to inflammatory bowel disease.